AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27234460 — intervention group
Group type: EXPERIMENTAL
Intervention: High polyunsaturated fat intake (6-12 g)
Number of subjects: 1672
Study 27234460 — intervention group
Group type: COMPARATOR
Intervention: Adjustment for maximum wall thickness, hypertension, hyperlipidemia, and diabetes
Number of subjects: 1672
Study 24794282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab monotherapy
Number of subjects: 255
Study 24794282 — intervention group
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy (PDT) combination therapy
Number of subjects: 255
Study 22177195 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents and Children Talking Together (PCTT)
Number of subjects: 78
Study 21223653 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite transplantation group (CT)
Number of subjects: 28
Study 21223653 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 28
Study 21223653 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 17661246 — intervention group
Group type: EXPERIMENTAL
Intervention: Information video on colonoscopy procedures and cleansing
Number of subjects: 162
Study 17661246 — intervention group
Group type: COMPARATOR
Intervention: No video
Number of subjects: 162
Study 16126926 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine
Number of subjects: 26
Study 16126926 — intervention group
Group type: COMPARATOR
Intervention: Gadopentetate dimeglumine
Number of subjects: 26
Study 12419644 — intervention group
Group type: EXPERIMENTAL
Intervention: New formulation of ticlopidine hydrochloride (250mg)
Number of subjects: 24
Study 12419644 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation Tiklid (250mg)
Number of subjects: 24
Study 9859745 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatine (Unigraft)
Number of subjects: 150
Study 9859745 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen (Hemashield)
Number of subjects: 150
Study 9859745 — intervention group
Group type: EXPERIMENTAL
Intervention: Human albumin (USCI)
Number of subjects: 150
Study 9859745 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 150
Study 7621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum containing 10 to 80 mg urea per piece, chewed for 10 minutes.
Number of subjects: 0
Study 7621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Two pieces of gum containing 20 mg urea each, chewed for 10 minutes.
Number of subjects: 0
Study 7621491 — intervention group
Group type: EXPERIMENTAL
Intervention: Three pieces of gum containing 20 mg urea each, chewed one after the other (10 + 10 + 10 min).
Number of subjects: 0
Study 7621491 — intervention group
Group type: COMPARATOR
Intervention: Conventional sugarless gum (control).
Number of subjects: 0
Study 2504375 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted diet (avoiding milk and other dairy products, eggs, fish, peanuts, and soybeans) for mothers who breast fed (49 mothers)
Number of subjects: 221
Study 2504375 — intervention group
Group type: COMPARATOR
Intervention: Casein hydrolysate formula for infants not breast fed (43 infants)
Number of subjects: 221
Study 2504375 — intervention group
Group type: COMPARATOR
Intervention: Soy milk formula for infants not breast fed (41 infants)
Number of subjects: 221
Study 2504375 — intervention group
Group type: COMPARATOR
Intervention: Cows milk formula for infants not breast fed (40 infants)
Number of subjects: 221
Study 331137 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide
Number of subjects: 20
Study 331137 — intervention group
Group type: COMPARATOR
Intervention: Meglumine metrizoate
Number of subjects: 20
Study 7226953 — intervention group
Group type: COMPARATOR
Intervention: Inhaled distilled water plus intramuscular (IM) saline solution
Number of subjects: 6
Study 7226953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled A dose of atropine plus IM saline solution
Number of subjects: 6
Study 7226953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled distilled water plus 0.35 mg IM atropine
Number of subjects: 6
Study 7226953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled A dose of atropine plus 0.35 mg IM atropine
Number of subjects: 6
Study 7226953 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled double the A dose plus IM saline solution
Number of subjects: 6
Study 30587857 — intervention group
Group type: EXPERIMENTAL
Intervention: EVIDENT II application and usual primary care counseling
Number of subjects: 597
Study 30587857 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual primary care counseling only)
Number of subjects: 597
Study 29334921 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Social Behaviour and Network Therapy (B‐SBNT) + Treatment as Usual (TAU)
Number of subjects: 83
Study 29334921 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Goal Setting (PGS) + Treatment as Usual (TAU)
Number of subjects: 83
Study 29334921 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 83
Study 27189286 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (1000 IU during screening, median doses of 2000 IU daily)
Number of subjects: 191
Study 24219351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy for psychosis
Number of subjects: 56
Study 23174592 — intervention group
Group type: EXPERIMENTAL
Intervention: SCIT plus ICS
Number of subjects: 100
Study 23174592 — intervention group
Group type: COMPARATOR
Intervention: ICS only
Number of subjects: 100
Study 20436046 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 209
Study 20436046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 17033909 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin‐cisplatin (AP) chemotherapy
Number of subjects: 317
Study 17033909 — intervention group
Group type: COMPARATOR
Intervention: Whole abdominal irradiation (WAI)
Number of subjects: 317
Study 15702045 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose azithromycin (30 mg/kg)
Number of subjects: 313
Study 15702045 — intervention group
Group type: COMPARATOR
Intervention: High dose amoxicillin (90 mg/kg/d, in 2 divided doses for 10 days)
Number of subjects: 313
Study 11999665 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (10-20 mg/day)
Number of subjects: 1217
Study 11999665 — intervention group
Group type: COMPARATOR
Intervention: Conventional lipid-lowering drugs (fibrates, nicotinic acid, probucol)
Number of subjects: 1217
Study 10458219 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 160 mg/d (one tablet per day)
Number of subjects: 368
Study 10458219 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 800 mg/d (five tablets per day)
Number of subjects: 368
Study 10458219 — intervention group
Group type: EXPERIMENTAL
Intervention: MA 1,600 mg/d (10 tablets per day)
Number of subjects: 368
Study 7636280 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (FLUC)
Number of subjects: 41
Study 7636280 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AB)
Number of subjects: 41
Study 2223648 — intervention group
Group type: EXPERIMENTAL
Intervention: Untreated stage A-CLL patients
Number of subjects: 309
Study 350254 — intervention group
Group type: EXPERIMENTAL
Intervention: Various existing methods of allocation to treatment groups
Number of subjects: 0
Study 350254 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 31999146 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Quality (PQ) from fathers
Number of subjects: 141
Study 31999146 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Time (PT)
Number of subjects: 141
Study 31999146 — intervention group
Group type: COMPARATOR
Intervention: Interparental Conflict (IPC)
Number of subjects: 141
Study 29991662 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator workshop (G2)
Number of subjects: 62
Study 29991662 — intervention group
Group type: COMPARATOR
Intervention: Theoretical explanation (G1)
Number of subjects: 62
Study 27473843 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg for 12 months
Number of subjects: 21
Study 27473843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 25342898 — intervention group
Group type: EXPERIMENTAL
Intervention: Olodaterol 5 μg once daily (via Respimat(®)) combined with tiotropium 18 μg once daily (via HandiHaler(®))
Number of subjects: 0
Study 25342898 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium 18 μg once daily (via HandiHaler(®)) combined with placebo (via Respimat(®))
Number of subjects: 0
Study 23773532 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric (80% of concentric‐eccentric 1RM, 4×7‐8)
Number of subjects: 4
Study 23773532 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard load eccentric only (80% of concentric‐eccentric 1RM, 4×12‐15 repetitions)
Number of subjects: 4
Study 23773532 — intervention group
Group type: EXPERIMENTAL
Intervention: High load eccentric (80% of eccentric 1RM, 4×7‐8 repetitions)
Number of subjects: 4
Study 23773532 — intervention group
Group type: COMPARATOR
Intervention: Control (no training)
Number of subjects: 4
Study 20035358 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline functional disability (Roland-Morris Disability Questionnaire scores)
Number of subjects: 273
Study 20035358 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline fear of movement (Tampa Scale for Kinesiophobia scores)
Number of subjects: 273
Study 20035358 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervisor social support and duration of complaints
Number of subjects: 273
Study 20035358 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-worker social support and pain radiation
Number of subjects: 273
Study 18585908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Number of subjects: 41
Study 18585908 — intervention group
Group type: EXPERIMENTAL
Intervention: Supralingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Number of subjects: 41
Study 18585908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual active group
Number of subjects: 41
Study 18585908 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 41
Study 16988729 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT) at a dose of 35-45 ml/kg/h
Number of subjects: 0
Study 16988729 — intervention group
Group type: COMPARATOR
Intervention: Continuous renal replacement therapy (CRRT)
Number of subjects: 0
Study 12798483 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cystectomy
Number of subjects: 40
Study 12798483 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 40
Study 11032586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 to 30 mg/d for >/= 2 years)
Number of subjects: 345
Study 11032586 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 345
Study 9362144 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental training and behavior-management training (6-week program)
Number of subjects: 30
Study 9362144 — intervention group
Group type: COMPARATOR
Intervention: Viewing family-related videotapes (6-week program)
Number of subjects: 30
Study 8252955 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (0.2 mg)
Number of subjects: 14
Study 8252955 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol (0.4 mg)
Number of subjects: 14
Study 8252955 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oxitropium and fenoterol (0.2 mg and 0.4 mg)
Number of subjects: 14
Study 8252955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2938479 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Occupational Functioning (AOF) screening tool
Number of subjects: 83
Study 31237939 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative atrial fibrillation (POAF)
Number of subjects: 18117
Study 28641369 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen (quintile 5 vs. quintile 1)
Number of subjects: 27071
Study 28641369 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble intercellular adhesion molecule‐1 (quintile 5 vs. quintile 1)
Number of subjects: 27071
Study 28641369 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐acetyl side‐chains of acute phase proteins
Number of subjects: 27071
Study 28641369 — intervention group
Group type: EXPERIMENTAL
Intervention: High‐sensitivity C‐reactive protein
Number of subjects: 27071
Study 27755488 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Number of subjects: 76
Study 27755488 — intervention group
Group type: COMPARATOR
Intervention: Transversus abdominis plane block
Number of subjects: 76
Study 24332238 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus active symptom control
Number of subjects: 168
Study 24332238 — intervention group
Group type: COMPARATOR
Intervention: Active symptom control alone
Number of subjects: 168
Study 22101223 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Spline Varying‐coefficient mixture model (NSV)
Number of subjects: 0
Study 22101223 — intervention group
Group type: COMPARATOR
Intervention: Conditional Linear Model (CLM)
Number of subjects: 0
Study 22101223 — intervention group
Group type: COMPARATOR
Intervention: Standard random‐effects model
Number of subjects: 0
Study 20541825 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive glucose control with gliclazide MR-based regimen
Number of subjects: 11140
Study 20541825 — intervention group
Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 11140
Study 18166300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic tenderness at 5 days
Number of subjects: 713
Study 18166300 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic tenderness at 30 days
Number of subjects: 713
Study 18166300 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term markers (pelvic tenderness)
Number of subjects: 713
Study 16173527 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 55
Study 16173527 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet restriction
Number of subjects: 55
Study 16173527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 12888362 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 12888362 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 0
Study 15602800 — intervention group
Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) 40 microg t.i.d. for 3 days
Number of subjects: 12
Study 15602800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 15602800 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluindione 20 mg
Number of subjects: 12
Study 8688266 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 23
Study 8688266 — intervention group
Group type: COMPARATOR
Intervention: Ketamine
Number of subjects: 23
Study 1848268 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg orally twice daily)
Number of subjects: 32
Study 1848268 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (0.6 mg/kg daily or 0.3 mg/kg in combination with flucytosine)
Number of subjects: 32
Study 1848268 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 32
Study 1848268 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B
Number of subjects: 32
Study 6676676 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 100 mg/day for 8 days
Number of subjects: 32
Study 6676676 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 days
Number of subjects: 32
Study 30868612 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 80
Study 30868612 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 80
Study 29915123 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13299
Study 29915123 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 13299
Study 26825975 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness Group (RG) with incentives
Number of subjects: 75
Study 26825975 — intervention group
Group type: COMPARATOR
Intervention: Readiness Group (RG) without incentives
Number of subjects: 75
Study 26825975 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness Group (RG)
Number of subjects: 75
Study 24325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative feedback after each response during training
Number of subjects: 24
Study 24325851 — intervention group
Group type: COMPARATOR
Intervention: Non-informative feedback during training
Number of subjects: 24
Study 24325851 — intervention group
Group type: EXPERIMENTAL
Intervention: Informative feedback
Number of subjects: 24
Study 24325851 — intervention group
Group type: COMPARATOR
Intervention: Non-informative feedback
Number of subjects: 24
Study 25083241 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time dosing of thiazide diuretics
Number of subjects: 0
Study 25083241 — intervention group
Group type: COMPARATOR
Intervention: Morning dosing of thiazide diuretics
Number of subjects: 0
Study 21036118 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG) - additional physical exercises for 4 weeks
Number of subjects: 18
Study 21036118 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - conventional rehabilitation for 4 weeks
Number of subjects: 18
Study 17166315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation program
Number of subjects: 0
Study 16281091 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment
Number of subjects: 6
Study 11873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Pravastatin 40 mg daily (arm 1)
Number of subjects: 56
Study 11873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Simvastatin 40 mg daily (arm 2)
Number of subjects: 56
Study 11873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Atorvastatin 40 mg daily (arm 3)
Number of subjects: 56
Study 11873000 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir (NFV) 1250 mg twice daily with Pravastatin 40 mg daily (arm 4)
Number of subjects: 56
Study 10468065 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (Lng-IUS)
Number of subjects: 82
Study 8675718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0
Study 8675718 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided mastery therapy
Number of subjects: 0
Study 1282585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 17
Study 1282585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 4058186 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous abdominoperineal rectum excision
Number of subjects: 421
Study 4058186 — intervention group
Group type: COMPARATOR
Intervention: Metachronous abdominoperineal rectum excision
Number of subjects: 421
Study 31254522 — intervention group
Group type: EXPERIMENTAL
Intervention: Onabotulinumtoxin A (200 units)
Number of subjects: 59
Study 31254522 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL saline)
Number of subjects: 59
Study 29215517 — intervention group
Group type: EXPERIMENTAL
Intervention: Midurethral sling
Number of subjects: 113
Study 29215517 — intervention group
Group type: COMPARATOR
Intervention: Burch retropubic urethropexy
Number of subjects: 113
Study 26026818 — intervention group
Group type: EXPERIMENTAL
Intervention: Unithermia(®) with MMC-C and hyperthermia (HT)
Number of subjects: 34
Study 25631970 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of ferrous sulfate twice a week for 16 weeks
Number of subjects: 200
Study 25631970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study 22921641 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 320
Study 22921641 — intervention group
Group type: COMPARATOR
Intervention: Attention control successful aging condition
Number of subjects: 320
Study 19782353 — intervention group
Group type: EXPERIMENTAL
Intervention: Single preovulatory intrauterine insemination (IUI) performed 24 hours after hCG administration
Number of subjects: 450
Study 19782353 — intervention group
Group type: EXPERIMENTAL
Intervention: Two IUIs performed 12 and 36 hours after hCG administration
Number of subjects: 450
Study 19782353 — intervention group
Group type: EXPERIMENTAL
Intervention: Single periovulatory IUI performed 36 hours after hCG administration
Number of subjects: 450
Study 18585494 — intervention group
Group type: EXPERIMENTAL
Intervention: Full prescription drug coverage (no copays, coinsurance, or deductibles) for statins, beta-blockers, ACE inhibitors, and angiotensin II receptor blockers.
Number of subjects: 1000
Study 18585494 — intervention group
Group type: COMPARATOR
Intervention: Current levels of pharmacy benefit (control group).
Number of subjects: 1000
Study 18585494 — intervention group
Group type: EXPERIMENTAL
Intervention: Full prescription drug coverage (no copays, coinsurance, or deductibles).
Number of subjects: 1000
Study 15742336 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic hematopoietic stem cell transplantation (allo‐HSCT)
Number of subjects: 0
Study 12042291 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 229
Study 12042291 — intervention group
Group type: COMPARATOR
Intervention: Surgical management
Number of subjects: 229
Study 12042291 — intervention group
Group type: COMPARATOR
Intervention: Preference-based management (both expectant and surgical)
Number of subjects: 229
Study 9180668 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention unit (n = 326)
Number of subjects: 650
Study 9180668 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 324)
Number of subjects: 650
Study 7609511 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-channel blockers
Number of subjects: 0